News Release
Genflow Biosciences advances three major programs in fight against ageing diseases
Genflow Biosciences PLC
Genflow Biosciences PLC CE Dr Eric Leire tells Proactive's Stephen Gunnion the company had a successful year in 2023, allowing it to expand its research and development pipeline. Leire highlighted three main programs during an interview. The first focuses on MASH (Metabolic Dysfunction-Associated Steatohepatitis), soon progressing to clinical trials, indicating a strong move towards addressing liver diseases. The second program deals with Werner Syndrome, a progeria-related condition, where Genflow is innovating with synthetic organoids to mimic human organ function for better clinical trial predictions. The third program targets sarcopenia in collaboration with Revatis SA, aiming to combat muscle loss associated with ageing. The company has also engaged with regulatory agencies in Europe and the US, receiving positive feedback on its approach, particularly with its MASH program. It is awaiting further feedback from the FDA to decide the trial's location. In addition to a recent £715,000 fundraise, Genflow's financial strategy relies heavily on grants, with recent significant funding from the Wallonia Region in Belgium, which Leire believes positions it well to continue its work without heavy reliance on venture capital. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 09, 2024 07:37 AM Eastern Daylight Time
Video
News Release
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic Inc
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Vitt said the quarter was notable for Immunic's successful fundraising efforts, raising up to $240 million in a three-tranche private placement aimed at furthering its Multiple Sclerosis (MS) and gastrointestinal treatments. He also highlighted the importance of the recent allowance of a fourth US patent for vidofludimus calcium, enhancing its intellectual property portfolio around MS treatments and ensuring long-term commercial exclusivity. Vitt gave an update on the status of ongoing clinical trials, including the advanced Phase 2 CALLIPER trial for MS, with significant results expected in April next year. Moreover, he touched on Immunic's gastrointestinal disorder programs, particularly for celiac disease, with the IMU-856 program showing promising results in restoring gut wall functions. The interview also covered upcoming milestones, focusing on executing current clinical trials and preparing for future phases. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com
May 09, 2024 06:58 AM Eastern Daylight Time
Video
News Release
Fusion Antibodies reports second-half rebound as new commercial strategy pays off
Fusion Antibodies PLC
Fusion Antibodies PLC (AIM:FAB) CEO Adrian Kinkaid joined Proactive's Stephen Gunnion with more on the company that specialises in various stages of antibody development, excluding GMP production for clinical trials. He described Fusion Antibodies as a collaborative research organisation that engages deeply with clients to develop therapeutic antibodies, one of the most complex scientific endeavours. Its client base includes small VC-funded biotechs and has expanded to include large organisations like the National Cancer Institute. Fusion Antibodies also explores adjacent markets such as diagnostics, family medicine, and veterinary medicine. Recently, the company faced economic challenges, particularly a decrease in venture capital for biotechs, impacting its core business. However, it responded with strategic diversifications and cost management, leading to a 47% increase in fourth-quarter 2024 sales compared to the first quarter. The order pipeline at the year's end was significantly stronger at £750,000, promising a solid foundation for future growth. Kinkaid noted that Fusion Antibodies has secured various agreements, including a notable collaboration with the National Cancer Institute to employ their OptiMAL technology platform for discovering human antibodies. This platform could potentially lead to multiple licensing opportunities due to its vast diversity. Additionally, the company raised about £1.37 million, which will fund growth initiatives, including expanding its commercial team to better reach its primary market in the USA. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com
May 09, 2024 06:41 AM Eastern Daylight Time
Video
News Release
Cloud DX secures 4th Provincial Health contract for remote patient monitoring
Cloud DX
Robert Kaul, CEO of Cloud DX, discussed with Steve Darling from Proactive the new Remote Patient Monitoring Agreement for Cloud DX RPM Services, which has been secured with a Canadian Provincial Health Authority. This agreement expands Cloud DX's provision of Connected Health remote patient monitoring products and services across Canada, now including contracts with Alberta, Yukon, Prince Edward Island, and a Master Services Agreement with Mohawk Medbuy—the country's largest hospital procurement agency. Kaul shared with Proactive that the contract spans 36 months and includes options for two 12-month extensions. Each subscription under these contracts is projected to average $1,520 CAD annually, covering the costs associated with the Connected Health Kit, which includes patient-prescribed hardware, software, and connectivity solutions. Over the four months leading up to April 30, 2024, Cloud DX has announced a significant growth milestone, securing 26 new contracts. These agreements span across hospitals, paramedic services, U.S. clinics, and include two Canadian provinces, marking a significant inflection point in the company’s expansion and presence in the healthcare industry. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com
May 08, 2024 02:48 PM Eastern Daylight Time
Video
News Release
Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office
Poolbeg Pharma PLC
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief legal officer John McEvoy joins Proactive's Stephen Gunnion with news that POLB 001's Immuno-modulator II has received the fully granted patent from the US Patent Office. McEvoy explained the patent encompasses a class of drugs for treating and preventing hypercytokinemia (cytokine storms) in patients triggered by an immune response, applicable across multiple disease indications. The granted patent further solidifies Poolbeg Pharma's robust intellectual property portfolio for POLB 001, potentially increasing the asset's value and making it more attractive to potential partners. McEvoy highlighted the company's ongoing efforts to strengthen and expand their IP portfolio, noting existing patents covering p38 MAP kinase inhibitors for influenza treatment and hypercytokinemia. Additional patents have been filed, particularly focusing on cancer immunotherapy applications of POLB 001. The company has also applied for patents concerning dosage regimens based on results from their recent LPs trial, aiming to protect innovations and maintain a competitive edge in the pharmaceutical market. This strategic IP protection is crucial for safeguarding the company's products and ensuring shareholder value, particularly as they seek partnerships to further develop POLB 001. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 08, 2024 08:32 AM Eastern Daylight Time
Video
News Release
Faron Pharmaceuticals' new CEO Dr Juho Jalkanen sets bold vision for 2024
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Limited (AIM:FARN) new CEO Dr Juho Jalkanen joined Proactive's Stephen Gunnion with his vision for the company. The founding member and former chief operating officer of Faron said one of his priorities is to meet with the US Food & Drug Administration earlier than planned in the hope of fast-tracking its lead drug, bexmarilimab, which has shown huge promise in treating a type of rare blood cancer. The move follows promising data from the phase I trials involving patients with myelodysplastic syndrome (MDS) who were unresponsive to a class of drugs called hypomethylating agents (HMAs). Jalkanen highlighted the company's ongoing phase 2 trial targeting relapsed refractory MDS, emphasising the strategic goal of securing non-dilutive funding and considering future mergers and acquisitions as the drug shows promise. Jalkanen also discussed the potential of the lead drug candidate in treating specific macrophage-driven cancers, indicating an optimistic outlook for the near term, including significant milestones expected in 2024. These milestones include more phase 2 data, expected by late May, and subsequent FDA feedback, pivotal for future planning. The CEO expressed confidence in the company's position and its appeal to investors, especially given the biotech sector's recovery from a period he referred to as a "nuclear winter." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 08, 2024 08:19 AM Eastern Daylight Time
Video
News Release
ANGLE announces second assay with AstraZeneca as it deepens relationship with pharma giant
ANGLE PLC
ANGLE PLC chief executive Andrew Newland joins Proactive's Stephen Gunnion with details of a supplier agreement with AstraZeneca PLC to develop an androgen receptor (AR) detection assay to enhance prostate cancer studies. With a contract value of £550,000, the project is scheduled for completion in the first quarter of next year. Newland said the agreement is an extension of a prior arrangement to develop a methodology for detecting CTC micronuclei and will use ANGLE's innovative Parsortix system. Successful development of this AR assay is expected to bolster the use of the Parsortix system in clinical oncology, particularly for assessing the efficacy of prostate cancer therapies. The discussion also touched upon the potential benefits of this development for ANGLE, suggesting it might significantly enhance the company's operations and market position. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 08, 2024 08:12 AM Eastern Daylight Time
Video
News Release
Creo Medical honoured with King's Award for Enterprise in Innovation
Creo Medical Group PLC
Creo Medical Group PLC (AIM: CREO) CEO Craig Gulliford joins Proactive's Stephen Gunnion with the news that the company has been recognised with the King's Award for Enterprise in Innovation, an accolade honouring innovative UK companies for their impact in their respective sectors. The award highlights Creo's influence on patient outcomes through their advanced medical technologies. Gulliford emphasised the rare honour, noting that among over five million companies in the UK, only 59 received this award this year. The company leverages a unique combination of bipolar radiofrequency energy with microwave energy, focusing on miniaturising surgical procedures. This innovation has led to significant advancements in treatment effectiveness and cost-efficiency, particularly noted in a recent NHS case study that showcased substantial economic benefits, including a reduction in theatre costs and patient hospital stays. This recognition allows Creo Medical Group to join a select group of internationally recognised brands, enhancing their credibility and market presence. Gulliford expressed pride in the team's achievement and optimism about future innovations, particularly in addressing complex medical conditions like lung cancer. The award not only validates past efforts but also sets a high standard for the company's ongoing commitment to healthcare innovation. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 08, 2024 07:50 AM Eastern Daylight Time
Video
News Release
Skye Bioscience Moves to Nasdaq, Hits Milestone in Clinical Program
Skye Bioscience Inc
Skye Bioscience CEO Punit Dhillon joined Steve Darling from Proactive to share news announcing the company's uplisting of its common stock to the Nasdaq stock exchange, trading under the ticker symbol "SKYE." This achievement signifies a significant milestone for the company, reflecting advancements in its Phase 2 clinical programs, financial position, and shareholder base. Dhillon further disclosed that Skye Bioscience reached another critical milestone by successfully dosing 56 patients with SBI-100 Ophthalmic Emulsion in its Phase 2a study and completing final study visits for all participants. SBI-100 OE, a cannabinoid receptor type 1 agonist administered topically to the eye, is designed to address the unmet needs of patients with elevated intraocular pressure related to primary open-angle glaucoma or ocular hypertension. Notably, all treated patients completed the study without early discontinuations due to adverse events, demonstrating the safety profile of SBI-100 OE. The company anticipates releasing topline data for the entire study in the second quarter, marking a significant milestone in advancing its clinical program. Skye Bioscience's move to the Nasdaq exchange underscores its commitment to enhancing visibility, expanding its investor base, and unlocking value for shareholders as it progresses in its mission to develop innovative therapies for ocular diseases. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com
May 07, 2024 11:59 AM Eastern Daylight Time
Video
